Article Figures & Data
Figures
- Figure 1
Flow chart of literature screening and selection process. tPA, tissue plasminogen activator.
- Figure 2
Forest plot for excellent outcome of IV-tPA-treated MIS compared with those without IV-tPA treatment. IV-tPA, intravenous recombinant tissue plasminogen activator; M-H, Mantel-Haenszel; MIS, mild ischaemic stroke.
- Figure 3
Funnel plot for publication bias for excellent outcome of intravenous recombinant tissue plasminogen activator-treated mild ischaemic stroke.
- Figure 4
Forest plot for symptomatic intracranial haemorrhage of IV-tPA-treated mild ischaemic stroke compared with those without IV-tPA treatment. IV-tPA, intravenous recombinant tissue plasminogen activator; M-H, Mantel-Haenszel.
- Figure 5
Forest plot for mortality of IV-tPA-treated mild ischaemic stroke compared with those without IV-tPA treatment. IV-tPA, intravenous recombinant tissue plasminogen activator; M-H, Mantel-Haenszel .
Tables
- Table 1
Characteristics of studies included in the review
Publication Origin Cases Definition Time to needle
(hours)Age Men Definition of sICH Baseline
NIHSS scoremRS 0–1 at 3 months or OHS 0–1 at
6 monthssICH Mortality at 3 months Khatri et al 21 USA 58 ≤5 <3 66.2 (12.0) 42 (72.4) ICH with NIHSS ≥1 4 (4) 46 (79.3) 1 (1.7) 1 (1.7) Huisa et al 18 USA 133 ≤5 <3 68.5 (15.4) 79 (59.4) ICH with NIHSS ≥1 2.6 (1.5) 85 (63.9) 3 (2.3) 6 (4.5) Urra et al 12 Spain 203 ≤5 <4.5 68.9 (13.5) 134 (66.0) ICH with NIHSS ≥4 3 (2–4)
2 (1–3.8)167 (82.3) 0 5 (2.5) Greisenegger et al 11 Austria 890 ≤5 <3 70 (61–78)
70 (62–78)518 (58.2) ICH with NIHSS ≥1 4 (3–5) 609 (68.4) 11 (1.2) 27 (3.0) Nesi et al 13 Italy 128 ≤6 <3 65.6 (11.6) 92 (71.9) ICH with NIHSS ≥1 NA 108 (84.4) 0 0 Khatri et al 14 USA 106 ≤5 <3 82
8163 (59.4) ICH with significant neurological deterioration 4 59 (55.7) 0 3 (2.8) Ng et al 16 Australia 73 ≤3 <4.5 73.2 (67.3–82.8) 45 (61.6) ICH with NIHSS ≥4 2 (1–3) 59 (80.8) 0 0
